ClinicalTrials.Veeva

Menu

Multi-component Real-time Remote Rehabilitation in Sarcopenia

S

Sichuan University

Status

Not yet enrolling

Conditions

Sarcopenia

Treatments

Behavioral: Control
Behavioral: dietary intake guidance and exercise guidance

Study type

Interventional

Funder types

Other

Identifiers

NCT06937073
WCHSCU-2024-2455

Details and patient eligibility

About

This study is designed as a single center, non blinded, randomized controlled, dual arm trial. We designed to allocate participants in a 1:1 ratio to compare the effects of real-time remote rehabilitation and self rehabilitation with multiple components on muscle strength, muscle mass, balance, and walking ability in patients with sarcopenia. Each participant signs an informed consent form before registering for the study. This protocol follows the 2013 Standard Protocol Project: Intervention Trial Recommendation Guidelines.

Full description

This study is designed as a single center, non blinded, randomized controlled, dual arm trial. We designed to allocate participants in a 1:1 ratio to compare the effects of real-time remote rehabilitation and self rehabilitation with multiple components on muscle strength, muscle mass, balance, and walking ability in patients with sarcopenia. Each participant signs an informed consent form before registering for the study. This protocol follows the 2013 Standard Protocol Project: Intervention Trial Recommendation Guidelines.

Enrollment

104 estimated patients

Sex

All

Ages

60 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

According to the diagnostic criteria for sarcopenia established by the Asian Working Group for Sarcopenia (AWGS):

  1. Low muscle strength:

    Handgrip strength < 28 kg for men, < 18 kg for women; and/or

  2. Low physical performance:

    Usual gait speed (6-Meter Gait Speed, 6MGS) ≤ 1.0 m/s; and/or

  3. Low muscle mass:

Skeletal Muscle Mass Index (SMI) < 7.0 kg/m² for men, < 5.7 kg/m² for women.

Exclusion criteria

  1. Unable or unwilling to undergo body composition measurement.
  2. Regular exercise habits within the past 6 months (resistance training ≥ 2 times/week, moderate-intensity aerobic exercise ≥ 3 times/week).
  3. History of unstable cardiovascular disease, stroke, diabetes, psychiatric disorders, or other contraindications to exercise in the past 6 months.
  4. Previously diagnosed with rheumatoid arthritis.
  5. History of conditions affecting motor coordination, such as poliomyelitis sequelae, epilepsy, or stroke sequelae.
  6. Presence of implanted medical devices due to previous fractures, heart disease, or other conditions.
  7. Diagnosis of malignant tumors.
  8. Unable to independently use the WeChat mini program used in this study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

104 participants in 2 patient groups

Arm 1
Experimental group
Description:
In the "Fugu Medical" WeChat mini program, the intervention plan for the intervention group included: (1) dietary intake guidance and (2) exercise guidance. (1) Dietary intake guidance: The dietary guidance was mainly based on the general dietary guidelines for the elderly issued by the Chinese Nutrition Society. (2) Exercise guidance Exercise guidance included resistance training and balance training.
Treatment:
Behavioral: dietary intake guidance and exercise guidance
Arm 2
Active Comparator group
Description:
Participants in the control group only received rehabilitation program articles in the form of images and text through the mobile application. These materials also included dietary intake guidance and exercise instructions. The frequency and intensity of the exercise instructions were sent to the patients at the same time. However, their daily adherence, including whether the training was completed or whether the dietary intake was appropriate, was not checked, verified, or followed up.
Treatment:
Behavioral: Control

Trial contacts and locations

0

Loading...

Central trial contact

Kexin Wang, MM; Linbo Peng, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems